Abstract
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystemic disease of unknown aetiology that is characterised by disabling chronic fatigue and involves both the immune and gastrointestinal (GI) systems. Patients display alterations in GI microbiome with a significant proportion experiencing GI discomfort and pain and elevated blood biomarkers for altered intestinal permeability compared with healthy individuals. To investigate a possible GI origin of ME/CFS we designed a feasibility study to test the hypothesis that ME/CFS pathogenesis is a consequence of increased intestinal permeability that results in microbial translocation and a breakdown in immune tolerance leading to generation of antibodies reactive to indigenous intestinal microbes. Secretory IgA and serum IgG levels and reactivity to intestinal microbes were assessed in five pairs of severe ME/CFS patients and matched same-household healthy controls. For profiling serum IgG we developed IgG-Seq which combines flow-cytometry based bacterial cell sorting and metagenomics to detect mucosal IgG reactivity to the microbiome. We uncovered evidence for immune dysfunction in severe ME/CFS patients that was characterised by reduced capacity and reactivity of serum IgG to stool microbes, irrespective of their source. This study provides the rationale for additional studies in larger cohorts of ME/CFS patients to further explore immune-microbiome interactions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KAS was supported by a PhD studentship jointly funded by Invest in ME Research (UK charity number 1153730) and the University of East Anglia. The authors gratefully acknowledge the support of the Biotechnology and Biological Sciences Research Council (BBSRC); The authors gratefully acknowledge the support of the Biotechnology and Biological Sciences Research Council (BBSRC); this research was supported by the BBSRC Institute Strategic Programme Grant Gut Microbes and Health BB/R012490/1 and its constituent projects BBS/E/F/000PR10353 and BBS/E/F/000PR10355 (SRC). MD and GS were funded by the BBSRC Core Capability Grant BB/CCG1860/1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was performed in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice (ICH GCP) Guideline, and in compliance with national law. The research was approved by the NHS Health Research Authority London Hampstead Research Ethics Committee (REC 17/LO/1102, IRAS ID 218545). This study was registered on the clinicaltrials.gov database (NCT03254823). All participants provided fully informed written consent. The collection, storage and use of human tissue samples was carried out within the terms of the Human Tissue Act 2004 (Human Tissue Authority).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The raw WMS data are available at the European Nucleotide Archive under study accession PRJEB61661.
